Posted by Michael Wonder on 18 Feb 2020
Novartis receives EC approval for Beovu, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
17 February 2020 - Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading phase.
Novartis today announced the European Commission (EC) has approved Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). Beovu is the first EC-approved anti-VEGF treatment to demonstrate superior resolution of retinal fluid, a key marker of disease activity, versus aflibercept (secondary endpoints).
Beovu also offers the ability to start eligible wet AMD patients on a three-month dosing interval immediately after the loading phase. The EC decision is applicable to all 27 European Union member states as well as the UK, Iceland, Norway and Liechtenstein.
